%PDF-1.4
1 0 obj
<</Type /Catalog /Pages 2 0 R>>
endobj
2 0 obj
<</Type /Pages /Kids [3 0 R] /Count 1>>
endobj
3 0 obj
<</Type /Page /Parent 2 0 R /Resources 4 0 R /MediaBox [0 0 612 792] /Contents 6 0 R>>
endobj
4 0 obj
<</Font <</F1 5 0 R /F2 7 0 R /F3 8 0 R>>>>
endobj
5 0 obj
<</Type /Font /Subtype /Type1 /BaseFont /Helvetica-Bold>>
endobj
7 0 obj
<</Type /Font /Subtype /Type1 /BaseFont /Helvetica>>
endobj
8 0 obj
<</Type /Font /Subtype /Type1 /BaseFont /Helvetica-Oblique>>
endobj
6 0 obj
<</Length 1300>>
stream
BT
/F1 18 Tf
50 750 Td
(LABORATORY REPORT: LIPID PANEL) Tj
ET

BT
/F1 12 Tf
50 720 Td
(PATIENT INFORMATION) Tj
ET

BT
/F2 10 Tf
50 700 Td
(Name: John Doe) Tj
0 -15 Td
(Date of Birth: 05/15/1980) Tj
0 -15 Td
(Patient ID: P-1001) Tj
0 -15 Td
(Collection Date: February 28, 2023) Tj
0 -15 Td
(Report Date: March 2, 2023) Tj
0 -15 Td
(Ordering Physician: Dr. Michael Chen) Tj
ET

BT
/F1 12 Tf
50 610 Td
(LIPID PANEL RESULTS) Tj
ET

BT
/F2 10 Tf
50 590 Td
(Test) Tj
200 0 Td
(Result) Tj
300 0 Td
(Reference Range) Tj
-500 -15 Td
(Total Cholesterol) Tj
200 0 Td
(195 mg/dL) Tj
300 0 Td
(<200 mg/dL) Tj
-500 -15 Td
(HDL Cholesterol) Tj
200 0 Td
(45 mg/dL) Tj
300 0 Td
(>40 mg/dL) Tj
-500 -15 Td
(LDL Cholesterol) Tj
200 0 Td
(120 mg/dL) Tj
300 0 Td
(<100 mg/dL) Tj
-500 -15 Td
(Triglycerides) Tj
200 0 Td
(150 mg/dL) Tj
300 0 Td
(<150 mg/dL) Tj
-500 -15 Td
(Non-HDL Cholesterol) Tj
200 0 Td
(150 mg/dL) Tj
300 0 Td
(<130 mg/dL) Tj
-500 -15 Td
(Total Cholesterol/HDL Ratio) Tj
200 0 Td
(4.3) Tj
300 0 Td
(<5.0) Tj
ET

BT
/F1 12 Tf
50 460 Td
(INTERPRETATION) Tj
ET

BT
/F2 10 Tf
50 440 Td
(- LDL cholesterol is borderline high $$>100 mg/dL$$.) Tj
0 -15 Td
(- Triglycerides are at the upper limit of normal range.) Tj
0 -15 Td
(- HDL cholesterol is acceptable but could be improved.) Tj
0 -15 Td
(- Non-HDL cholesterol is elevated.) Tj
ET

BT
/F1 12 Tf
50 370 Td
(RECOMMENDATIONS) Tj
ET

BT
/F2 10 Tf
50 350 Td
(1. Continue current statin therapy $$Atorvastatin 20mg daily$$.) Tj
0 -15 Td
(2. Dietary modifications recommended: reduce saturated fat and increase fiber intake.) Tj
0 -15 Td
(3. Regular exercise of at least 150 minutes per week is advised.) Tj
0 -15 Td
(4. Follow-up lipid panel in 3 months to assess response to therapy.) Tj
ET

BT
/F1 12 Tf
50 280 Td
(CARDIOVASCULAR RISK ASSESSMENT) Tj
ET

BT
/F2 10 Tf
50 260 Td
(Based on the patient's lipid profile and other risk factors $$hypertension, diabetes$$,) Tj
0 -15 Td
(the estimated 10-year ASCVD risk is moderate.) Tj
ET

BT
/F3 10 Tf
50 210 Td
(This laboratory report is confidential and intended only for the addressee.) Tj
ET

BT
/F2 10 Tf
50 170 Td
(Laboratory Director: James Wilson, MD, PhD) Tj
0 -15 Td
(Reviewed by: Dr. Michael Chen) Tj
0 -15 Td
(Central Medical Laboratory, CLIA #: 12D3456789) Tj
ET
endstream
endobj
xref
0 9
0000000000 65535 f
0000000009 00000 n
0000000056 00000 n
0000000111 00000 n
0000000212 00000 n
0000000267 00000 n
0000000335 00000 n
0000000401 00000 n
0000000469 00000 n
trailer
<</Size 9/Root 1 0 R>>
startxref
1753
%%EOF
